LY-334370

LY-334370
Names
Preferred IUPAC name
4-Fluoro-N-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]benzamide
Other names
LY-334,370
Identifiers
CAS Number
3D model (JSmol)
ChemSpider
MeSH C108218
PubChem CID
UNII
InChI
  • InChI=1S/C21H22FN3O/c1-25-10-8-14(9-11-25)19-13-23-20-7-6-17(12-18(19)20)24-21(26)15-2-4-16(22)5-3-15/h2-7,12-14,23H,8-11H2,1H3,(H,24,26) ☒N
    Key: MDMJLMDBRQXOOI-UHFFFAOYSA-N ☒N
  • InChI=1/C21H22FN3O/c1-25-10-8-14(9-11-25)19-13-23-20-7-6-17(12-18(19)20)24-21(26)15-2-4-16(22)5-3-15/h2-7,12-14,23H,8-11H2,1H3,(H,24,26)
    Key: MDMJLMDBRQXOOI-UHFFFAOYAA
SMILES
  • CN1CCC(c2c3cc(N([H])C(c4ccc(F)cc4)=O)ccc3n([H])c2)CC1
Properties
Chemical formula
 C21H22FN3O
Molar mass 351.425 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)
Infobox references

LY-334370 is a selective 5-HT1F receptor agonist[1] which was under development by Eli Lilly and Company for the treatment of migraine headaches.[2] The drug showed efficacy in a phase II clinical trial[3] but further development was halted due to toxicity detected in animals.[4]

See also

References

  1. ↑ Dupuis DS, Colpaert FC, Pauwels PJ (1998). "G-protein activation at 5-HT1A receptors by the 5-HT1F ligand LY-334,370 in guinea-pig brain sections and recombinant cell lines". Br. J. Pharmacol. 124 (2): 283–90. doi:10.1038/sj.bjp.0701832. PMC 1565387. PMID 9641544.
  2. ↑ Shepheard S, Edvinsson L, Cumberbatch M, Williamson D, Mason G, Webb J, Boyce S, Hill R, Hargreaves R (1999). "Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY-334,370". Cephalalgia. 19 (10): 851–8. doi:10.1046/j.1468-2982.1999.1910851.x. PMID 10668103. S2CID 8439008.
  3. ↑ Goldstein DJ, Roon KI, Offen WW, Ramadan NM, Phebus LA, Johnson KW, Schaus JM, Ferrari MD (2001). "Selective seratonin 1F (5-HT1F) receptor agonist LY334370 for acute migraine: a randomised controlled trial". Lancet. 358 (9289): 1230–4. doi:10.1016/S0140-6736(01)06347-4. PMID 11675061. S2CID 39926402.
  4. ↑ Ramadan NM, Buchanan TM (2006). "New and future migraine therapy". Pharmacol. Ther. 112 (1): 199–212. doi:10.1016/j.pharmthera.2005.04.010. PMID 16797716.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.